Onconetix Stock Soars 10.24% on Nasdaq Listing Relief

Onconetix's stock surged by 10.24% in pre-market trading on June 18, 2025, marking a significant rise for the biotech company.

Onconetix has secured continued listing on the Nasdaq exchange following a favorable decision from the Nasdaq Hearings Panel. The company must meet specific compliance requirements by June 13, 2025, to maintain its listing status. This decision comes as a relief for Onconetix, which has been focusing on men's health and oncology innovations.

The Nasdaq Hearings Panel's approval allows Onconetix to continue its operations without the threat of delisting. The company has completed a 1-for-85 reverse stock split to meet the listing requirements, demonstrating its commitment to compliance and transparency.

This positive development is expected to boost investor confidence in Onconetix, as the company continues to innovate in the biotech sector. The continued listing on Nasdaq provides Onconetix with the platform to attract more investors and expand its market presence.